Pharma News
07 Apr 2024 to 13 Apr 2024
Apr 9, 2024
Antiepileptic Drugs Market Expected to Surpass $26.30 Billion by 2031 Amid Regulatory and Safety Challenges...
The global antiepileptic drugs market is projected to reach a value of USD 26.30 billion by 2031, with a CAGR of 4.70% during the forecast period. The market is driven by the increasing prevalence of neurological disorders, government investments, and market expansion strategies by key players. However, regulatory risks, patent expirations, and geopolitical issues pose challenges to market growth. The market is segmented based on drug generation and distribution channels, with the first generation and hospitals/pharmacies holding the highest shares. North America is expected to dominate the market, with China leading the APAC region. Online pharmacies are gaining more attention. Major players in the market include Merck KGaA, Eisai Co. Ltd., Novartis AG, and Pfizer Inc.
Apr 9, 2024
The Drugs Advisory Board of the Health Ministry suggests banning Emcure Pharma's pain medication ...
The Drugs Technical Advisory Board (DTAB) has recommended the prohibition of the pain relief drug combination S(+) etodolac+paracetamol manufactured by Emcure Pharmaceuticals. The DTAB had previously recommended the prohibition, but Emcure Pharmaceuticals obtained a favorable order from the Delhi High Court. However, in a recent meeting, the DTAB agreed to prohibit the manufacture, sale, and distribution of the drug combination. The combination was previously prohibited by the government in 2018 due to potential risks. Emcure Pharmaceuticals argued that their version of the combination had advantages, but the DTAB disagreed.
Apr 9, 2024
Examining the potential dangers and advantages of weight-loss medications such as Ozempic in health news
The weight-loss drugs Ozempic and Wegovy, both brand names of the drug semaglutide, have gained popularity and are being prescribed by clinicians in the US. Studies have shown that semaglutide can help in weight loss, with participants losing a significant amount of body weight. It may also reduce chronic disease risk factors and improve quality of life. However, potential side effects include gastrointestinal symptoms, fatigue, and intolerance to the drug. There are also concerns about access to the medication and conflicts of interest in its marketing. It is important to take a holistic approach to health and consult with healthcare providers before using weight-loss medications.
Apr 8, 2024
Daewoong applies for authorization for South Korea's first domestically produced SGLT2 diabetes medication Envlo in Mexico
Daewoong Pharmaceutical has applied for product approval for Envlo, its homegrown sodium-glucose cotransporter 2 (SGLT2) diabetes drug, in Mexico. The application utilizes clinical data from Korea, allowing the company to forego additional clinical trials in Mexico. Envlo has demonstrated non-inferiority to existing treatments and offers several advantages over other SGLT-2 inhibitors. Daewoong has been actively seeking to enter international markets and expects substantial sales from Mexico, contributing to an overall contract value exceeding 100 billion won.
Apr 8, 2024
Biocon is at the forefront of the competition to develop generic versions of popular weight loss medications before their patents expire.
Indian pharmaceutical company Biocon is focusing on anti-obesity therapies as the patents for blockbuster drugs are set to expire, opening the market to generic alternatives. Biocon has gained UK approval for the first generic version of liraglutide injectable, with other peptide formulations also under development. The company is aiming to maintain its lead position in the market, which is expected to reach $100bn by 2030. Other pharmaceutical giants, including Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla, are also developing their own anti-obesity drugs.
Apr 8, 2024
Teva authorized to distribute generic version of Pfizer's popular drug Effexor XR
The U.S. FDA has approved Teva Pharmaceutical Industries' generic version of Pfizer's antidepressant, Effexor XR. Teva will have a 180-day period of marketing exclusivity, during which no other generic company can sell their version. This comes as Pfizer is expected to lose a significant portion of its sales as customers shift to the cheaper generic option. Teva shares remained flat in premarket trading, while Pfizer's fell nearly 1%.
Apr 8, 2024
Biocon's generic weight loss medications receive a boost with approval from UK regulatory authorities - Mint
Indian pharmaceutical company Biocon is shifting its focus to anti-obesity therapies as patents for blockbuster obesity medications start to expire. The company has secured UK approval for the first generic version of liraglutide injectable, sold under the brand name Saxenda by Novo Nordisk. Saxenda is among the first weight-loss drugs in this category to lose patent protection, and Biocon is anticipating a "jackpot" as other generic versions of obesity medications enter the market. The company is also developing 15 peptide formulations, with one or two seeking regulatory approval this year.
Apr 8, 2024
Biora Therapeutics Reveals Latest Patent for BioJet™ Liquid Jet Delivery Technology
Biora Therapeutics has been issued a new patent for its BioJet platform for oral, systemic delivery of biotherapeutics. The patent covers key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract. The platform's potential to deliver large molecules, such as GLP-1 agonists and monoclonal antibodies, could transform oral delivery of therapeutics. Biora holds a comprehensive patent position with approximately 12 issued patents and 31 pending applications for its delivery platform and methods for using it to treat diseases.
Apr 8, 2024
Biocon is at the forefront of India's advancement in lucrative weight-loss medications with the development of Saxenda patents - Mint
Indian pharma company Biocon has received regulatory approval in the UK for the first generic version of liraglutide injectable, a weight loss drug. The drug, which is losing patent protection in November, is sold by Novo Nordisk under the brand name Saxenda. Biocon is aiming to enter the anti-obesity market, which is projected to reach $100bn by 2030. Other Indian drugmakers, including Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla, are also developing anti-obesity drugs.
Apr 8, 2024
Biocon Expands into Anti-Obesity Drugs, Targeting Lucrative $100 Billion Market - News Track
Indian pharmaceutical company Biocon Ltd. is focusing on developing medications to address obesity as patents for popular drugs expire. This follows the recent approval of Biocon's generic version of liraglutide injectable, a weight loss medication, in the UK. The company aims to seek regulatory approval for one or two drugs this year and has filed applications with US and European regulators. Other major players in the Indian pharmaceutical industry, including Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., and Cipla Ltd., are also developing their own anti-obesity medications.
Apr 7, 2024
Is there a New Development that Could Boost the Stocks of Eli Lilly and Novo Nordisk?
A phase 2 clinical trial involving a GLP-1-targeted molecule called lixisenatide has shown promising results in slowing the progression of motor disability symptoms in patients with Parkinson's disease. This development has significant implications for Novo Nordisk and Eli Lilly, two leading pharmaceutical companies that produce GLP-1 drugs. The market for GLP-1 therapies is estimated to be worth up to $71 billion by 2032, and the potential market for Parkinson's medicines could reach $6.1 billion in 2033. Further clinical trials will be needed to confirm the efficacy of GLP-1 drugs in treating Parkinson's.
